RIBEIRO J.
- Country
- France
- Department
- Oncologie Médicale
Research Overview
- Evaluation of Preoperative Durvalumab (MEDI4736) in Patients with Early-Stage Untreated Small Triple Negative Breast Cancer
- Phase 1 Study of OP-3136 in Patients with Advanced or Metastatic Solid Tumors
- Comparative Evaluation of Giredestrant and Triptorelin Versus Anastrozole and Triptorelin in Premenopausal ER-Positive/HER2-Negative Early Breast Cancer
Data & Insights
Has run more than one trial at 79 of 235 partner sites.
Specializations
Early-phase solid tumor oncology
Clinical activity centers on advanced and metastatic solid tumors, with particular attention to molecularly selected cancers and treatment-resistant disease. The portfolio includes non-small cell lung cancer, gastrointestinal malignancies, pancreatic cancer, urothelial carcinoma, and head and neck squamous cell carcinoma.
- Advanced solid tumors
- Metastatic non-small cell lung cancer
- Gastrointestinal and pancreatic cancers
- Urothelial and head and neck cancers
Work in this area reflects a strong focus on new therapeutic options for difficult-to-treat solid malignancies at Institut Gustave Roussy.
Hematologic malignancies
Research involvement extends across acute myeloid leukemia, myelodysplastic syndromes, chronic lymphocytic leukemia, and aggressive B-cell lymphomas. The clinical landscape also includes multiple myeloma and other relapsed or refractory blood cancers.
- Acute myeloid leukemia
- Myelodysplastic syndromes
- B-cell lymphomas
- Multiple myeloma
The therapeutic emphasis includes innovation in relapsed disease and biomarker-defined hematologic cancer populations.
Breast and gynecologic cancers
Clinical interests include breast cancer across hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative subtypes, as well as ovarian cancer, endometrial cancer, cervical cancer, and related gynecologic malignancies.
- Hormone receptor-positive breast cancer
- Triple-negative breast cancer
- Ovarian cancer
- Endometrial and cervical cancers
This area includes interest in targeted and immuno-oncology strategies for recurrent, metastatic, and biomarker-selected disease.
Genomically driven precision oncology
The investigator is active in cancers defined by EGFR, ALK, RET, ROS1, FGFR, KRAS, HER2, IDH1, and MTAP alterations. This includes tumor types selected by DNA repair deficiency, mismatch repair deficiency, microsatellite instability, and other actionable molecular features.
- Targeted therapy in molecularly selected tumors
- HER2-altered and EGFR-mutant cancers
- MTAP-deleted and KRAS-mutant tumors
- DNA repair and mismatch repair–defined disease
These studies support the development of biomarker-guided treatment approaches across multiple histologies.
Sarcoma, melanoma, and rare tumors
Additional involvement covers soft tissue sarcoma, osteosarcoma, gastrointestinal stromal tumor, melanoma, mesothelioma, and selected rare tumors, including neuroendocrine neoplasms and thymic malignancies.
- Soft tissue and bone sarcomas
- Melanoma
- Mesothelioma
- Rare neuroendocrine and thymic tumors
The therapeutic scope includes challenging rare cancers with limited standard options and high unmet medical need.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.